Channel
@BiopharmaBot_News
On this record: Growth · Engagement · Posts · Citations · Cite this entry
120subscribers
+14 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1003991007657 |
|---|---|
| Type | Channel |
| Username | @BiopharmaBot_News |
| Created | Between 1 April 2026 and 31 July 2026— estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 9 August 2026 |
| Last confirmed live | 14 August 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 14 August 2026 |
| On Telegram | t.me/BiopharmaBot_News |
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 14 Aug 2026, 06:35 | 120 | +14 |
| 9 Aug 2026, 08:46 | 106 | no change |
| 7 Aug 2026, 13:32 | 106 | first reading |
20 posts held, back to 7 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 pageof Telegram’s post history, 20 posts per page.
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
| Window | Rolling 30 days · latest post in window 8 August 2026 |
|---|---|
| Posts held | 20 (7 August 2026 – 8 August 2026) |
| Views total | 301 |
| Reactions total | — |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 9 Aug 2026, 08:46 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias 🏛️ 규제 | ⚪ LOW RiboX Therapeutics Ltd.는 자가면역 혈구감소증(autoimmune cytopenias) 치료를 위한 원형 RNA(circRNA) 기반 in vivo CAR-T 치료제 RXIM002의 IND 신청이 FDA로부터 승인되었다고 발표했다. RXIM002는 표적 지질나노입자(tLNP)에 봉입된 circRNA를 T세포에 직접 전달하여 CD19 표적 CAR를 체내에서 발현시키는 방식으로, 기존 ex vivo 제조 공정을 우회한다. 이번 IND 승인은 tLNP-circR…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 📰 기타 | ⚪ LOW ORIC Pharmaceuticals(NASDAQ:ORIC)는 2026년 7월 입사한 비임원 신규 직원 5명에게 2026년 8월 3일자로 비적격 주식 옵션 125,400주 및 양도제한조건부주식(RSU) 20,550주를 부여했다. 해당 부여는 Nasdaq Rule 5635(c)(4)에 따라 이사회 보상위원회의 승인을 받아 시행됐다. 📌 원문: https://www.globenewswire.com/news-release/2026/08/07/3341394/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 📰 기타 | ⚪ LOW Intellia Therapeutics(NASDAQ:NTLA)는 2026년 8월 1일 신규 직원 8명에게 고용 유인 목적으로 2024 Inducement Plan에 따른 주식 보상을 부여했다고 발표했다. 📌 원문: https://www.globenewswire.com/news-release/2026/08/07/3341377/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
BINSA legislation to limit biotech deals in China unveiled in Senate 📋 정책 | 🟡 MID 미국 상원에서 중국과의 바이오테크·제약 딜을 제한하는 법안 BINSA(Biotech and Innovation National Security Act 추정)가 발의됐다. 하원에서 먼저 작성된 법안을 상원이 이어받은 것으로, 민주당 상원의원 Elissa Slotkin(미시간주)이 발의에 참여했다. 📌 원문: https://endpoints.news/binsa-legislation-to-limit-biotech-deals-in-china-unveiled-in-senate/
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial 🏛️ 규제 | 🟡 MID FDA가 9월에 자문위원회(adcomm)를 열어 Grail의 암 조기 검출 검사(multi-cancer early detection test)를 심의할 예정이다. 해당 검사는 영국에서 실시된 대규모 무작위 임상시험에서 1차 평가변수를 달성하지 못한 바 있어 논란이 되고 있다. 📌 원문: https://endpoints.news/fda-to-hold-adcomm-for-grail-cancer-test-that-failed-in-large-randomized-trial/
Lilly's Zepbound remains physicians' favorite, even as oral obesity launches altar landscape 📰 기타 | ⚪ LOW Spherix Global Insights의 의료 전문가 설문조사에 따르면, 주사형 체중감량제가 최신 경구형 치료제 대비 의사 선호도에서 큰 격차로 앞서고 있으며, Eli Lilly(NYSE:LLY)의 티르제파타이드(Zepbound, GIP/GLP-1 이중 작용제)가 선두를 유지하고 있다. 📌 원문: https://www.fiercepharma.com/pharma/even-launch-obesity-pills-lillys-zepbound-remains-overwhelming-favorite-among-physicians
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts 💰 펀딩 | ⚪ LOW BlossomHill Therapeutics와 Latigo Biotherapeutics가 각각 예상 대비 최소 30% 이상을 초과 조달하며 IPO를 성공적으로 완료했다. 📌 원문: https://www.fiercebiotech.com/biotech/blossomhill-latigo-outshine-ipo-expectations-oversubscribed-debuts
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy 📰 기타 | ⚪ LOW Boston 소재 바이오텍 Ensoma는 희귀 면역질환 대상 선도 유전자치료제 개발에 역량을 집중하기 위해 추가 인력 감축을 단행하고 전임상 프로그램을 중단했다. 이번 조치는 지난해 11월 인력의 절반을 감축한 데 이은 두 번째 구조조정이다. 📌 원문: https://www.fiercebiotech.com/biotech/ensoma-sheds-more-staff-pauses-preclinical-programs-home-lead-gene-therapy
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth 📊 실적 | ⚪ LOW Novo Nordisk(코펜하겐:NOVO-B) CFO Karsten Munk Knudsen이 2분기 실적 발표 당일 Fierce Biotech와 인터뷰하며 회사의 재무적 '롤러코스터' 여정과 변화하는 사업 환경 속 성장 압박을 언급했다. 또한 비만·당뇨 복합 치료제 카그리세마(cagrisema, GLP-1/아밀린 이중작용제)에 대한 낙관적 시각을 재확인했다. 📌 원문: https://www.fiercebiotech.com/biotech/its-been-rollercoaster-novo-nordisks-cfo-reflects-pressure-drive-gro…
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million 💰 펀딩 | ⚪ LOW Femasys Inc.(NASDAQ:FEMY)는 Nantahala Capital 주도, Rosalind Advisors 및 경영진 참여 하에 $30M 규모의 사모 증자(private placement) 계약을 체결했다. 워런트 전량 현금 행사 시 최대 $90M의 추가 자금 조달이 가능하다. 이번 거래는 2026년 8월 10일경 종결될 예정이며, 동사는 여성 대상 가임력 및 비수술적 영구 피임 솔루션을 개발하는 기업이다. 📌 원문: https://www.globenewswire.com/news-release/2026/08/07/3341129/0/en/…
BioMarin axes $270M rare disease asset after missing phase 3 endpoint 🧬 임상시험 | 🔴 HIGH BioMarin Pharmaceutical(NASDAQ:BMRN)이 희귀질환 파이프라인 자산 BMN 401의 전 적응증 개발을 종료했다. 이번 결정은 Phase 3 임상에서 혼재된 결과(mixed data)를 보고한 지 수개월 만에 이루어졌으며, 해당 자산의 가치는 약 $270M으로 평가되었다. 📌 원문: https://www.fiercebiotech.com/biotech/biomarin-axes-270m-rare-disease-asset-after-missing-phase-3-endpoint
CurePSP Announces Enrollment of First Participant in the PSP Trial Platform 🧬 임상시험 | 🟡 MID CurePSP가 주도하고 University of California, San Francisco(UCSF)가 이끄는 진행성 핵상 마비(PSP) 플랫폼 임상시험(PSP Trial Platform, PTP)이 첫 번째 참가자를 등록했다. PTP는 National Institute on Aging(NIA)의 5년간 최대 $75.4M 그랜트로 자금을 조달하며, 전국 50개 임상 기관에서 진행된다. 플랫폼 임상 설계를 채택해 복수의 약물을 동시에 시험하며, 새로운 약물도 지속 추가할 수 있다. 2년간 440명 참가자 등록을 목표로 하며, 첫 1년간 참가자의 75%가 활성 약물을 투여받…
Showing the 12 most recent of 20 posts we hold for @BiopharmaBot_News. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank — 758,655 of 1,336,469entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 14 August 2026 — this entry's latest reading, not the date you are reading this.
“바이오파마봇 레이더 v1.0” (@BiopharmaBot_News), 120 subscribers as measured 14 August 2026. Telegram Register, tgregister.com/channel/BiopharmaBot_News.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.